NasdaqCM - Delayed Quote USD

Biofrontera Inc. (BFRI)

1.1700 -0.0900 (-7.14%)
At close: May 13 at 4:00 PM EDT
1.2500 +0.08 (+6.84%)
After hours: May 13 at 5:56 PM EDT
Loading Chart for BFRI
DELL
  • Previous Close 1.2600
  • Open 1.2500
  • Bid 1.1200 x 100
  • Ask 1.2300 x 100
  • Day's Range 1.1600 - 1.3000
  • 52 Week Range 0.6100 - 13.4200
  • Volume 177,161
  • Avg. Volume 624,668
  • Market Cap (intraday) 5.955M
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) --
  • EPS (TTM) -13.0200
  • Earnings Date Aug 11, 2024 - Aug 26, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 16.00

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

www.biofrontera-us.com

83

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BFRI

Performance Overview: BFRI

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BFRI
57.76%
S&P 500
9.47%

1-Year Return

BFRI
85.48%
S&P 500
26.61%

3-Year Return

BFRI
--
S&P 500
13.38%

5-Year Return

BFRI
--
S&P 500
13.38%

Compare To: BFRI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BFRI

Valuation Measures

Annual
As of 5/10/2024
  • Market Cap

    6.41M

  • Enterprise Value

    10.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.06

  • Price/Book (mrq)

    1.34

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -59.08%

  • Return on Assets (ttm)

    -33.86%

  • Return on Equity (ttm)

    -140.43%

  • Revenue (ttm)

    34.07M

  • Net Income Avi to Common (ttm)

    -20.13M

  • Diluted EPS (ttm)

    -13.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.42M

  • Total Debt/Equity (mrq)

    112.64%

  • Levered Free Cash Flow (ttm)

    -24.79M

Research Analysis: BFRI

Company Insights: BFRI

Research Reports: BFRI

People Also Watch